324 related articles for article (PubMed ID: 21691123)
21. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
Jacobson TA
Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
[TBL] [Abstract][Full Text] [Related]
22. [Residual risk of cardiovascular complications and its reduction with a combination of lipid lowering agents].
Soska V
Vnitr Lek; 2011 Mar; 57(3):313-6. PubMed ID: 21495414
[TBL] [Abstract][Full Text] [Related]
23. Comparative effectiveness of statin plus fibrate combination therapy and statin monotherapy in patients with type 2 diabetes: use of propensity-score and instrumental variable methods to adjust for treatment-selection bias.
Suh HS; Hay JW; Johnson KA; Doctor JN
Pharmacoepidemiol Drug Saf; 2012 May; 21(5):470-84. PubMed ID: 22461130
[TBL] [Abstract][Full Text] [Related]
24. Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus.
Reyes-Soffer G; Rondon-Clavo C; Ginsberg HN
Expert Opin Pharmacother; 2011 Jun; 12(9):1429-38. PubMed ID: 21426238
[TBL] [Abstract][Full Text] [Related]
25. Hyperlipidaemia and cardiovascular disease: do fibrates have a role?
Saha SA; Arora RR
Curr Opin Lipidol; 2011 Aug; 22(4):270-6. PubMed ID: 21519250
[TBL] [Abstract][Full Text] [Related]
26. [Multimodal therapy of dyslipidemia].
Stahn A; Hanefeld M
Clin Res Cardiol Suppl; 2011 May; 6():10-6. PubMed ID: 22528173
[TBL] [Abstract][Full Text] [Related]
27. [Therapeutic targets in the treatment of dyslipidemia: HDL and non-HDL cholesterol].
Brea Hernando ÁJ
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():3-6. PubMed ID: 25043539
[TBL] [Abstract][Full Text] [Related]
28. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Hausenloy DJ; Yellon DM
Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
[TBL] [Abstract][Full Text] [Related]
29. Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?
Agouridis AP; Rizos CV; Elisaf MS; Filippatos TD
Rev Diabet Stud; 2013; 10(2-3):171-90. PubMed ID: 24380091
[TBL] [Abstract][Full Text] [Related]
30. Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient.
Watts GF; Karpe F
Heart; 2011 Mar; 97(5):350-6. PubMed ID: 21296781
[TBL] [Abstract][Full Text] [Related]
31. Use of fibrates in clinical practice: Queensland Lipid Group consensus recommendations.
Hamilton-Craig I; Kostner KM; Woodhouse S; Colquhoun D
Int J Evid Based Healthc; 2012 Sep; 10(3):181-90. PubMed ID: 22925614
[TBL] [Abstract][Full Text] [Related]
32. A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome.
Davidson M
Am J Cardiol; 2008 Dec; 102(12A):19L-27L. PubMed ID: 19084086
[TBL] [Abstract][Full Text] [Related]
33. Reducing cardiovascular risk in diabetes: beyond glycemic and blood pressure control.
Hobbs FD
Int J Cardiol; 2006 Jun; 110(2):137-45. PubMed ID: 16289373
[TBL] [Abstract][Full Text] [Related]
34. The role of fenofibrate in clinical practice.
Zambon A; Cusi K
Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S15-20. PubMed ID: 17935056
[TBL] [Abstract][Full Text] [Related]
35. Management of diabetic retinopathy: could lipid-lowering be a worthwhile treatment modality?
Dodson PM
Eye (Lond); 2009 May; 23(5):997-1003. PubMed ID: 19169236
[TBL] [Abstract][Full Text] [Related]
36. [Diabetic dyslipoproteinemia: beyond LDL].
Merkel M
Dtsch Med Wochenschr; 2009 May; 134(20):1067-73. PubMed ID: 19421932
[TBL] [Abstract][Full Text] [Related]
37. Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus.
Jones PH
Am J Cardiol; 2007 Feb; 99(4A):133B-140B. PubMed ID: 17307065
[TBL] [Abstract][Full Text] [Related]
38. Dyslipidaemia in diabetic patients: time for a rethink.
Shepherd J
Diabetes Obes Metab; 2007 Sep; 9(5):609-16. PubMed ID: 17697054
[TBL] [Abstract][Full Text] [Related]
39. The role of statins in managing diabetic dyslipidemia.
Toth PP
J Fam Pract; 2010 May; 59(5 Suppl):S23-9. PubMed ID: 20544054
[TBL] [Abstract][Full Text] [Related]
40. Benefits of lipid-lowering therapy in patients with type 2 diabetes mellitus.
Betteridge J
Am J Med; 2005 Dec; 118 Suppl 12A():10-5. PubMed ID: 16356802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
